PT  - JOURNAL ARTICLE
AU  - Benjamin Faucher
AU  - Rania Assab
AU  - Jonathan Roux
AU  - Daniel Levy-Bruhl
AU  - Cécile Tran Kiem
AU  - Simon Cauchemez
AU  - Laura Zanetti
AU  - Vittoria Colizza
AU  - Pierre-Yves Boëlle
AU  - Chiara Poletto
TI  - Reactive vaccination of workplaces and schools against COVID-19
AID  - 10.1101/2021.07.26.21261133
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.07.26.21261133
4099  - http://medrxiv.org/content/early/2021/07/29/2021.07.26.21261133.short
4100  - http://medrxiv.org/content/early/2021/07/29/2021.07.26.21261133.full
AB  - As vaccination against COVID-19 stalls in some countries, increased accessibility and more adaptive approaches may be useful to keep the epidemic under control. Here we study the impact of reactive vaccination targeting schools and workplaces where cases have been detected, with an agent-based model accounting for COVID-19 natural history, vaccine characteristics, individuals’ demography and behaviour and social distancing. We study epidemic scenarios ranging from sustained spread to flare-up of cases, and we consider reactive vaccination alone and in combination with mass vaccination. With the same number of doses, reactive vaccination reduces cases more than non-reactive approaches, but may require concentrating a high number of doses over a short time in case of sustained spread. In case of flare-ups, quick implementation of reactive vaccination supported by enhanced test-trace-isolate practices would limit further spread. These results provide key information to promote an adaptive vaccination plan in the months to come.Competing Interest StatementThe authors have declared no competing interest.Funding StatementWe acknowledge financial support from Haute Autorité de Santé; the ANR and Fondation de France through the project NoCOV (00105995); the Municipality of Paris (https://www.paris.fr/) through the programme Emergence(s); EU H2020 grants MOOD (H2020-874850), and RECOVER (H2020-101003589); Institut des Sciences du Calcul et de la Donnée (ISCD).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All relevant ethical guidelines have been followed.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesCode and input files of the study are posted on the github repository https://github.com/PYB-SU/ReactiveVaccination